DK0914155T3 - Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen - Google Patents

Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen

Info

Publication number
DK0914155T3
DK0914155T3 DK97917121T DK97917121T DK0914155T3 DK 0914155 T3 DK0914155 T3 DK 0914155T3 DK 97917121 T DK97917121 T DK 97917121T DK 97917121 T DK97917121 T DK 97917121T DK 0914155 T3 DK0914155 T3 DK 0914155T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
psma
prostate
extracellular domain
membrane antigen
Prior art date
Application number
DK97917121T
Other languages
Danish (da)
English (en)
Inventor
Gerald P Murphy
Alton L Boynton
Eric H Holmes
William T Tino
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24490004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0914155(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex Inc filed Critical Medarex Inc
Application granted granted Critical
Publication of DK0914155T3 publication Critical patent/DK0914155T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK97917121T 1996-03-25 1997-03-25 Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen DK0914155T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62139996A 1996-03-25 1996-03-25

Publications (1)

Publication Number Publication Date
DK0914155T3 true DK0914155T3 (da) 2006-06-26

Family

ID=24490004

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97917121T DK0914155T3 (da) 1996-03-25 1997-03-25 Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen

Country Status (10)

Country Link
EP (1) EP0914155B1 (fr)
JP (1) JP4295826B2 (fr)
AT (1) ATE318147T1 (fr)
AU (1) AU725583B2 (fr)
CA (1) CA2250141C (fr)
DE (1) DE69735294T2 (fr)
DK (1) DK0914155T3 (fr)
ES (1) ES2260788T3 (fr)
IL (1) IL126314A (fr)
WO (1) WO1997035616A1 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070782B1 (en) 1992-11-05 2006-07-04 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6953668B1 (en) 1992-11-05 2005-10-11 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen
WO1996026272A1 (fr) 1995-02-24 1996-08-29 Sloan-Kettering Institute For Cancer Research Antigene membranaire specifique de la prostate et ses utilisations
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6150508A (en) * 1996-03-25 2000-11-21 Northwest Biotherapeutics, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
GB2328871A (en) * 1997-09-05 1999-03-10 Merck & Co Inc Compositions for inhibiting platelet aggregation
AU3305699A (en) * 1998-02-26 1999-09-15 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
DE69941187D1 (de) * 1998-06-01 2009-09-10 Agensys Inc Serpentintransmembranantigene exprimiert in menschlichem krebs und deren verwendungen
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
WO2000050457A1 (fr) * 1999-02-22 2000-08-31 Beckman Coulter, Inc. Antigenes d'enveloppe prostatique specifique, ses procedes de production et d'utilisation
ES2277846T3 (es) * 1999-07-29 2007-08-01 Medarex, Inc. Anticuerpos monoclonales humanos para antigeno prostatico especifico.
EP1710256A1 (fr) * 1999-07-29 2006-10-11 Medarex, Inc. Anticorps monoclonaux humains de l'antigène d'enveloppe prostatique spécifique
FR2797743B1 (fr) * 1999-08-23 2003-08-08 Urogene Lignee cellulaire prostatique et son utilisation pour l'obtention d'une tumeur prostatique etablie chez l'animal
US6653129B1 (en) * 1999-09-13 2003-11-25 The Regents Of The University Of Colorado Method for isolation of cells from a solution
JP4838436B2 (ja) * 2001-04-04 2011-12-14 積水メディカル株式会社 抗ヒト肝性トリグリセリドリパーゼ抗体
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
CA2447695C (fr) 2001-06-01 2015-02-24 Cornell Research Foundation, Inc. Anticorps modifies diriges contre l'antigene prostatique specifique membranaire et utilisations associees
IL159422A0 (en) 2001-09-20 2004-06-01 Cornell Res Foundation Inc Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
US20040161776A1 (en) * 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
WO2003034903A2 (fr) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Anticorps et multimeres de proteines psma
ES2314272T3 (es) 2003-01-10 2009-03-16 Millennium Pharmaceuticals, Inc. Metodos para el diagnostico y el tratamiento del cancer.
CA2598454C (fr) 2005-02-18 2013-04-09 Medarex, Inc. Anticorps monoclonaux diriges contre l'antigene d'enveloppe specifique de la prostate (psma) depourvus de residus fucosyle
EP3300739A3 (fr) * 2005-03-31 2018-07-18 Agensys, Inc. Anticorps et molécules correspondantes se liant aux protéines 161p2f10b
EP1726650A1 (fr) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Anticorps monoclonaux et fragments d'anticorps monocaténaires contre l'antigène spécifique de surface membranaire de la prostate
EP1934261B1 (fr) 2005-09-26 2014-10-29 Medarex, L.L.C. Anticorps monoclonaux humains diriges contre cd70
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
US8940298B2 (en) 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
JP5286370B2 (ja) * 2008-02-29 2013-09-11 アイメック 細胞酵素ベースのバイオセンサ
EP2326350B1 (fr) 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Composés pour tuer des cellules cancéreuses exprimant psma et résistantes au taxane
JP5906090B2 (ja) 2009-02-17 2016-04-20 コーネル・リサーチ・ファンデーション・インコーポレイテッドＣｏｒｎｅｌｌ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃｏｒｐｏｒａｔｅｄ 癌の診断のための方法およびキットならびに治療価の推定
CA3040276A1 (fr) 2009-12-02 2011-06-09 Imaginab, Inc. Minobodies j591 et cys-diabodies pour le ciblage de l'antigene membranaire specifique de la prostate humaine (psma), et procedes d'utilisation
SG194567A1 (en) 2011-04-21 2013-12-30 Seattle Genetics Inc Novel binder-drug conjugates (adcs) and their use
BR112013027224A8 (pt) 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
AU2014372833B2 (en) 2013-12-23 2019-08-22 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP)
SG11201710639YA (en) 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
CN108136012B (zh) 2015-08-07 2022-10-04 伊麦吉纳博公司 靶向分子的抗原结合构建体
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
SG10202008909VA (en) 2016-03-24 2020-10-29 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
WO2017216028A1 (fr) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Conjugués anticorps-médicament spécifiques (adc) avec inhibiteurs de ksp et des anticorps anti-cd123
US12059472B2 (en) 2016-12-21 2024-08-13 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
AU2017380871C1 (en) 2016-12-21 2025-05-15 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
KR20200130709A (ko) 2018-03-06 2020-11-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 전립선-특이 막 항원 car 및 이의 사용 방법
CN112469440B (zh) 2018-06-18 2024-09-06 优瑞科生物技术公司 靶向前列腺特异性膜抗原(psma)的构建体和其用途
EP3830132B1 (fr) 2018-07-31 2022-11-23 Heidelberg Pharma Research GmbH Anticorps humanisés dirigés contre psma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757695A3 (fr) * 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Antigene de membrane spécifique à la prostate
WO1996026272A1 (fr) * 1995-02-24 1996-08-29 Sloan-Kettering Institute For Cancer Research Antigene membranaire specifique de la prostate et ses utilisations
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins

Also Published As

Publication number Publication date
EP0914155B1 (fr) 2006-02-22
IL126314A (en) 2003-07-31
EP0914155A1 (fr) 1999-05-12
AU725583B2 (en) 2000-10-12
DE69735294D1 (de) 2006-04-27
WO1997035616A1 (fr) 1997-10-02
IL126314A0 (en) 1999-05-09
JP4295826B2 (ja) 2009-07-15
EP0914155A4 (fr) 2001-05-16
ES2260788T3 (es) 2006-11-01
JP2001503601A (ja) 2001-03-21
CA2250141C (fr) 2008-07-29
AU2555297A (en) 1997-10-17
CA2250141A1 (fr) 1997-10-02
DE69735294T2 (de) 2006-09-21
ATE318147T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
DK1064303T3 (da) Monoklonale antistoffer, der er specifikke for det prostataspecifikke membranantigens ekstracellulære domæne
AU733544C (en) Treatment and diagnosis of cancer
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
PT973550E (pt) Anticorpos antagonistas anti-integrina avb3
ATE395362T1 (de) Monoklonale antikörper zur apoptosis-induzierung
NO981745D0 (no) Monoklonalt antistoff BR110 og anvendelse av dette
DE69731977D1 (de) Spezifische antikörper für dendritische zellen
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DE69128543D1 (de) Monoklonale antikörper der maus
ATE336512T1 (de) Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe
PT807124E (pt) Anticorpo monoclonal contra o receptor tirosina-quinase flt4 e sua utilizacao em diagnostico e terapeutica
ES2142070T3 (es) Utilizacion de un complejo ficobiliproteina-peptido de enlace como trazador fluorescente.
DE69504959D1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
ATE532796T1 (de) Immunassays zur spezifischen bestimmung von scca- isoformen
FI973418A0 (fi) Vasta-ainetuotannon toteaminen
AR023204A1 (es) Anticuerpos contra la proteina placentaria 13.
GB9826758D0 (en) Detection method